ImmunoCellular Therapeutics, Ltd.
21900 Burbank Boulevard
3rd Floor
Woodland Hills,
CA 91367
United States - Map
Phone: 818-992-2907
Fax: 818-992-2908
Website: http://www.imuc.com
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. Its lead pipeline product is ICT-107, a therapeutic dendritic cell (DC) vaccine, which is in Phase IIb clinical trial for the treatment of glioblastoma multiforme (GBM) that is a common and lethal type of brain cancer. The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM, as well as solid tumors, including ovarian, pancreatic, and breast cancers; ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells; and ICT-109, a monoclonal antibody product candidate to detect pancreatic and lung cancer in plasma and serum. In addition, it has a differential immunization for antigen and antibody discovery (DIAAD) platform that utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The company is based in Woodland Hills, California. Key Statistics
| |
| ImmunoCellular Therapeutics, Ltd.’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 7. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. John S. Yu M.D., Ph.D.,
49
Chairman, Founder, Chief Scientific Officer, Member of Exec. Committee and Member of Strategy Committee | 216.00K | 0.00 | Mr. Andrew Gengos ,
49
Chief Exec. Officer, Pres and Director | 33.00K | 0.00 | Mr. David E. Fractor CPA,
53
Principal Accounting Officer, VP of Fin. and Treasurer | 136.00K | 0.00 | Dr. James G. Bender Ph.D., M.P.H.,
63
VP of Product Devel. & Manufacturing | 221.00K | 43.00K | Mr. Sanford J. Hillsberg J.D.,
65
Co-Founder | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.02(0.79%) 4:01PM EDT